Skip to main
MASI

Masimo (MASI) Stock Forecast & Price Target

Masimo (MASI) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 25%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Masimo is a medical technology company that operates in the healthcare segment, with a focus on patient monitoring technologies and hospital automation solutions. The company has a strong pipeline of new products and is dedicated to generating evidence for clinical outcomes and cost of care reductions. Masimo also has a diverse customer base, including hospitals, emergency medical services, and physician offices. With a consistent track record of HSD top-line growth and guidance for a 7%-10% revenue CAGR, along with a projected 30% operating margin and $8 adjusted EPS by 2028, Masimo shows a sustainable outlook with a potential for consistent performance in the MedTech industry.

Bears say

Masimo is facing significant challenges, including ongoing legal battles, lack of diversification in their single business segment, and the need for aggressive market share expansion plans to meet their ambitious long-term targets. Recent refinancing activities and strategic initiatives may provide temporary relief from financial pressure, but the company's heavy reliance on pulse oximetry and other non-invasive patient monitoring technologies may leave them vulnerable to technological disruptions and competition in the future. The company's underlying adjusted EBIT margins have consistently fallen short of their long-term target, and tariffs could negatively impact future profitability.

Masimo (MASI) has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 25% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Masimo and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Masimo (MASI) Forecast

Analysts have given Masimo (MASI) a Buy based on their latest research and market trends.

According to 4 analysts, Masimo (MASI) has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $188, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $188, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Masimo (MASI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.